PRQR on Nasdaq
ProQR Therapeutics N.V.
We are a clinical-stage biotechnology company focused on advancing a pipeline of RNA editing therapeutics based on our proprietary Axiomer RNA-editing platform.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerPRQR on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersP71
- Incorporated inNetherlands3
- Business addressZernikedreef 9, Leiden3
- Filer categoryAccelerated filer3
See how the biggest companies compare on our leaderboards
We are a clinical-stage biotechnology company focused on advancing a pipeline of RNA editing therapeutics based on our proprietary Axiomer RNA-editing platform. Our lead program, AX-0810 for cholestatic diseases targeting NTCP, is currently being evaluated in a Phase 1 clinical trial in healthy volunteers. With funding from the Rett Syndrome Research Trust, we are also advancing AX-2402 targeting methyl CpG binding protein 2 mutations for Rett syndrome, a severe neurodevelopmental disorder. Additional pipeline programs include AX-2911 targeting PNPLA3 for metabolic dysfunction-associated steatohepatitis, AX-1412 targeting the B4GALT1 gene for CVDs, as well as a number of additional discovery-stage programs. In addition to our own pipeline programs, we have a partnership with Lilly, currently focused on up to 10 targets based on our Axiomer platform. Our ongoing discovery and screening ef…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 4 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | 15.9M EUR | 18.9M EUR | 6.5M EUR | |
| Other income | 441.0K EUR | 640.0K EUR | 3.0M EUR | |
| Research and development costs | -44.7M EUR | -36.4M EUR | -25.1M EUR | |
| General and administrative costs | -15.1M EUR | -13.7M EUR | -16.2M EUR | |
| Total operating costs | -59.8M EUR | -50.0M EUR | -41.4M EUR | |
| Operating result | -43.4M EUR | -30.5M EUR | -31.9M EUR | |
| Financial income | 2.3M EUR | 3.3M EUR | 2.6M EUR | |
| Financial expense | -1.3M EUR | -1.1M EUR | -1.5M EUR | |
| Gain on disposal of associate | 514.0K EUR | |||
| Gain on disposal of subsidiary | 92.0K EUR | |||
| Results related to derecognition of financial liabilities | 1.9M EUR | |||
| Results related to financial liabilities measured at FVTPL | 235.0K EUR | 345.0K EUR | 953.0K EUR | |
| Result before corporate income taxes | -42.2M EUR | -28.0M EUR | -27.8M EUR | |
| Corporate income taxes | -19.0K EUR | 197.0K EUR | 78.0K EUR | |
| Result for the year | -42.2M EUR | -27.8M EUR | -27.7M EUR | |
| Fair value loss on investment in financial asset designated as at FVTOCI | -621.0K EUR | |||
| Foreign operations - foreign currency translation differences | -1.1M EUR | 533.0K EUR | -395.0K EUR | |
| Owners of the Company | -42.2M EUR | -27.8M EUR | -28.1M EUR | |
| Non-controlling interests | 384.0K EUR | |||
| Owners of the Company | -43.3M EUR | -27.2M EUR | -29.1M EUR | |
| Non-controlling interests | 384.0K EUR | |||
| Total comprehensive loss | -43.3M EUR | -27.2M EUR | -28.8M EUR | |
| Weighted average number of shares outstanding (basic) | 105.3M shares | 86.1M shares | 81.0M shares | |
| Weighted average number of shares outstanding, diluted | 105.3M shares | 86.1M shares | 81.0M shares | |
| Basic loss per share | -0.40 EUR | -0.32 EUR | -0.35 EUR | |
| Diluted loss per share | -0.40 EUR | -0.32 EUR | -0.35 EUR |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Property, plant and equipment | 12.6M EUR | 14.1M EUR | 16.9M EUR | |
| Non-current assets | 12.6M EUR | 14.1M EUR | ||
| Other taxes | 913.0K EUR | 690.0K EUR | ||
| Trade and other receivables | 6.8M EUR | 3.7M EUR | ||
| Cash and cash equivalents | 92.4M EUR | 149.4M EUR | 118.9M EUR | 94.8M EUR |
| Current assets | 100.1M EUR | 153.8M EUR | ||
| Total assets | 112.8M EUR | 168.0M EUR | ||
| Share capital | 4.3M EUR | 4.3M EUR | ||
| Share premium | 483.9M EUR | 483.8M EUR | ||
| Reserves | 28.7M EUR | 27.6M EUR | ||
| Accumulated deficit | -467.5M EUR | -427.2M EUR | ||
| Equity attributable to owners of the Company | 49.4M EUR | 88.6M EUR | ||
| Total equity | 49.4M EUR | 88.6M EUR | 41.4M EUR | 66.7M EUR |
| Lease liabilities | 9.5M EUR | 11.1M EUR | ||
| Deferred income | 21.4M EUR | 29.4M EUR | ||
| Non-current liabilities | 30.9M EUR | 40.5M EUR | ||
| Borrowings | 4.9M EUR | 4.6M EUR | ||
| Lease liabilities | 1.5M EUR | 1.6M EUR | ||
| Derivative financial instruments | 234.0K EUR | 468.0K EUR | ||
| Trade payables | 298.0K EUR | 16.0K EUR | ||
| Social securities and other taxes | 1.5M EUR | |||
| Deferred income | 17.6M EUR | 21.9M EUR | ||
| Other current liabilities | 7.9M EUR | 8.8M EUR | ||
| Current liabilities | 32.4M EUR | 38.9M EUR | ||
| Total liabilities | 63.4M EUR | 79.4M EUR | ||
| Total equity and liabilities | 112.8M EUR | 168.0M EUR |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Property, plant and equipment | 12.6M EUR | 14.1M EUR | 16.9M EUR | |
| Non-current assets | 12.6M EUR | 14.1M EUR | ||
| Other taxes | 913.0K EUR | 690.0K EUR | ||
| Trade and other receivables | 6.8M EUR | 3.7M EUR | ||
| Cash and cash equivalents | 92.4M EUR | 149.4M EUR | 118.9M EUR | 94.8M EUR |
| Current assets | 100.1M EUR | 153.8M EUR | ||
| Total assets | 112.8M EUR | 168.0M EUR | ||
| Share capital | 4.3M EUR | 4.3M EUR | ||
| Share premium | 483.9M EUR | 483.8M EUR | ||
| Reserves | 28.7M EUR | 27.6M EUR | ||
| Accumulated deficit | -467.5M EUR | -427.2M EUR | ||
| Equity attributable to owners of the Company | 49.4M EUR | 88.6M EUR | ||
| Total equity | 49.4M EUR | 88.6M EUR | 41.4M EUR | 66.7M EUR |
| Lease liabilities | 9.5M EUR | 11.1M EUR | ||
| Deferred income | 21.4M EUR | 29.4M EUR | ||
| Non-current liabilities | 30.9M EUR | 40.5M EUR | ||
| Borrowings | 4.9M EUR | 4.6M EUR | ||
| Lease liabilities | 1.5M EUR | 1.6M EUR | ||
| Derivative financial instruments | 234.0K EUR | 468.0K EUR | ||
| Trade payables | 298.0K EUR | 16.0K EUR | ||
| Social securities and other taxes | 1.5M EUR | |||
| Deferred income | 17.6M EUR | 21.9M EUR | ||
| Other current liabilities | 7.9M EUR | 8.8M EUR | ||
| Current liabilities | 32.4M EUR | 38.9M EUR | ||
| Total liabilities | 63.4M EUR | 79.4M EUR | ||
| Total equity and liabilities | 112.8M EUR | 168.0M EUR |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Result for the year | -42.2M EUR | -27.8M EUR | -27.7M EUR |
| Other income | -441.0K EUR | -640.0K EUR | -3.0M EUR |
| Depreciation | 2.7M EUR | 2.8M EUR | 2.5M EUR |
| Results on derecognition of subsidiary | -131.0K EUR | ||
| Share-based compensation | 4.0M EUR | 2.5M EUR | 3.1M EUR |
| Financial income and expenses | -1.0M EUR | -2.2M EUR | -1.1M EUR |
| Results related to derecognition of financial liabilities | -1.9M EUR | ||
| Results related to financial liabilities measured at FVTPL | -235.0K EUR | -345.0K EUR | -953.0K EUR |
| Income tax expenses / (gains) | 19.0K EUR | -197.0K EUR | -78.0K EUR |
| Changes in deferred income | -12.0M EUR | -12.7M EUR | -6.5M EUR |
| Other changes in working capital | -5.4M EUR | -536.0K EUR | 55.4M EUR |
| Cash (used in) / generated by operations | -54.6M EUR | -39.1M EUR | 19.7M EUR |
| Corporate income tax (paid) / received | -19.0K EUR | 197.0K EUR | 78.0K EUR |
| Interest received | 2.3M EUR | 3.3M EUR | 2.6M EUR |
| Interest paid | -518.0K EUR | -770.0K EUR | -789.0K EUR |
| Net cash (used in) / generated by operating activities | -52.8M EUR | -36.4M EUR | 21.5M EUR |
| Purchases of property, plant and equipment | -1.0M EUR | -1.4M EUR | -1.4M EUR |
| Proceeds from sale of property, plant and equipment | 60.0K EUR | ||
| Proceeds from sale of intellectual property | 7.9M EUR | ||
| Transaction costs on sale of intellectual property | -2.7M EUR | -2.4M EUR | |
| Increase in short-term deposits | -17.0M EUR | ||
| Decrease in short-term deposits | 17.0M EUR | ||
| Net cash (used in) / generated by investing activities | -1.0M EUR | -4.1M EUR | 4.3M EUR |
| Proceeds from issuance of shares, net of transaction costs | 71.6M EUR | ||
| Proceeds from exercise of share options | 69.0K EUR | 223.0K EUR | 354.0K EUR |
| Repayment of convertible loans | -1.0M EUR | ||
| Repayment of lease liability | -1.9M EUR | -1.6M EUR | -1.6M EUR |
| Net cash (used in) / generated by financing activities | -1.8M EUR | 70.3M EUR | -2.3M EUR |
| Net (decrease) / increase in cash and cash equivalents | -55.6M EUR | 29.8M EUR | 23.6M EUR |
| Currency effect cash and cash equivalents | -1.3M EUR | 673.0K EUR | 599.0K EUR |
No quarter-by-quarter statement was filed.
Leadership
Who has led ProQR Therapeutics N.V., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
- Chief financial officerDennis Hom Mar 18, 2026 to now11
Board members and other officers (9)
- Chief Scientific OfficerGerardus Johannes Platenburg Mar 18, 2026 to now12
- Board memberAlison Francis Lawton Mar 18, 2026 to now13
- Board memberBart Filius Mar 18, 2026 to now14
- Board memberBegona Carreno-Gomez Mar 18, 2026 to now15
- Board memberDomenico Valerio Mar 18, 2026 to now16
- Board memberGerardus Johannes Platenburg Mar 18, 2026 to now12
- Board memberMartin Alexander Maier Mar 18, 2026 to now17
- Board memberTheresa Heggie Mar 18, 2026 to now18
- Board memberGylvin Lykke Hinsch Jun 2, 2026 to now19
Former names
- ProQR Therapeutics B.V.Jul 11, 2014 to Oct 3, 20143
Filings
162 filings to the SEC since October 2021: 5 annual reports, 18 insider forms, 30 large holders, 109 other. The latest 20:
- Sep 23, 20266-K EDGAR
- Sep 9, 20266-K EDGAR
- Aug 13, 20266-K EDGAR
- Aug 13, 20266-K EDGAR
- Aug 3, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 29, 2026SCHEDULE 13G EDGAR
- Jul 29, 2026SCHEDULE 13D/A EDGAR
- Jul 24, 2026SCHEDULE 13G/A EDGAR
- Jul 21, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 15, 2026EFFECT EDGAR
- Jul 15, 2026424B5 EDGAR
- Jul 15, 2026SCHEDULE 13G/A EDGAR
- Jul 13, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 6, 2026F-3 EDGAR
- Jun 30, 2026SCHEDULE 13D/A EDGAR
- Jun 30, 20264/A OWNERSHIP DOCUMENT EDGAR
- Jun 30, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 26, 20266-K EDGAR
- Jun 26, 2026424B5 EDGAR
The 162 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | de Boer Daniel AntonChief Executive Officer | Buy | 200,000 | $1.77 | $354.0K | Form 4 |
| Jul 17, 2026 | Filius BartDirector | Buy | 150,000 | $1.72 | $258.0K | Form 4 |
| Jul 9, 2026 | de Boer Daniel AntonChief Executive Officer | Buy | 150,000 | $1.74 | $261.0K | Form 4 |
| Jul 7, 2026 | de Boer Daniel AntonChief Executive Officer | Buy | 150,000 | $1.59 | $238.5K | Form 4 |
| Jun 26, 2026 | Filius BartDirector | Buy | 150,000 | $1.54 | $231.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Aberdeen Group plcSCHEDULE 13G, 1 filing Jul 29, 202620
- VAN HERK INVESTMENTS B.V.SCHEDULE 13D/A, 12 filings Sep 14, 2023 to Jul 29, 202621
- Eli Lilly and CompanySCHEDULE 13G/A, 1 filing Jul 24, 202622
- Privium Fund Management B.V.SCHEDULE 13G/A, 2 filings Jan 20, 2026 to Jul 15, 202623
- Adage Capital Management, L.P.SCHEDULE 13G/A, 3 filings Feb 12, 2025 to Aug 12, 202524
- RTW INVESTMENTS, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202325
- ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 202326
- Aescap Life Sciences StichtingSC 13G/A, 2 filings Feb 4, 2022 to Feb 9, 202327
- FMR LLCSC 13G/A, 2 filings Feb 9, 2022 to Feb 9, 202328
- Wellington Management CompanySC 13G/A, 2 filings Feb 4, 2022 to May 9, 202229
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARDennis Hom, Chief financial officer
- 12
- 13SEC EDGARAlison Francis Lawton, Board member
- 14SEC EDGARBart Filius, Board member
- 15SEC EDGARBegona Carreno-Gomez, Board member
- 16SEC EDGARDomenico Valerio, Board member
- 17SEC EDGARMartin Alexander Maier, Board member
- 18SEC EDGARTheresa Heggie, Board member
- 19SEC EDGARGylvin Lykke Hinsch, Board member
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29